Bonne Co., Ltd. Overview
Bonne is a small-cap Korean beauty and household-products company with two businesses. The first is an asset-light ("fabless") cosmetics ODM business that designs, formulates and packages products for overseas brands and retailers, mainly US and European indie brands such as Pixi, and has production done by outside contract manufacturers. The second is a portfolio of owned brands, led by the colour-cosmetics line Touch in SOL. Since 2021 it has also owned a majority stake in Atosafe, an eco-positioned detergent, fabric-softener and oral-care brand company, which contributed about 39% of revenue in Q2 2026. Bonne grew to a peak of KRW 72.9B in revenue (FY2023) on US indie-brand demand. It then entered a crisis: an SFC accounting sanction for inventory overstatement, a trading halt, falling ODM orders, consecutive losses and a near-breach of KOSDAQ market-cap listing thresholds. In July–October 2026, control passed to former Ourhome Chairwoman Koo Mi-hyun, who injected about KRW 22.2B of new capital. The investment case is now a turnaround and control-change story rather than a growth story.
What the company does
Bonne operates in three areas:
-
Cosmetics ODM/OEM. Bonne develops products for third-party brands. Its services cover concept, formulation, packaging and component sourcing, then delivery of finished goods labelled with the client's brand. It owns no manufacturing plants: production is outsourced to contract manufacturers while Bonne keeps R&D, product planning and design. This model has been described as "factory-less" or asset-light (Cosinkorea, 6 Aug 2026; IB Tomato, 7 Aug 2026). Bonne reports exporting to about 30 countries and having launched seven of its own brands (IB Tomato, Aug 2026). Management says ODM work is turnkey, running from product planning to mass production, and that some products first launched in 2009 are still being reordered (Herald Economy, Mar 2026).
-
Own cosmetics brands. The main brands are Touch in SOL (colour cosmetics, sold historically at Sephora US, Ulta, CVS, Japanese drugstores and Korean home shopping, and since March 2026 on Olive Young online) and Stage Q (co-developed with Sephora China).
-
Household and oral care (Atosafe subsidiary). Atosafe sells laundry detergent (Shussler), fabric softener (Milk Cotton) and toothpaste (Denti Buongiorno) through Korean online and TV-shopping channels such as Home&Shopping and Coupang. Its products are made by OEM manufacturers (Dealsite, Jun 2023). In February 2026 it signed its first mainland China distribution agreement.
The company's registered business purposes, as summarised by aggregators from its filings, are broad. They include baby care, bath, cleansing, eye make-up and colour cosmetics, fragrance, hair dye and hair care, nail, shaving, skincare, deodorant and depilatory products; import/export of cosmetics and health foods; wholesale and retail; chemical manufacturing; advertising; real-estate leasing; and detergent, toothpaste and lamp manufacturing and distribution (StockHub company profile).
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue type | Mostly product sales. ODM sales are B2B; brand and Atosafe sales are B2B2C through retailers and platforms. No material subscription or licensing revenue has been identified, although ODM sampling for subscription boxes (Boxycharm) was a meaningful channel in 2019–2022. |
| Segment mix (Q2 2026) | Cosmetics 59%, detergent 39%, other 2% (Butler, segment split per Q2 2026 filing) |
| Historical ODM/brand split | FY2020: ODM 64%, brand 34%, other 2% (SK Securities, 1 Apr 2021) |
| Value-chain position | Mid-stream. Bonne sits between raw-material and packaging suppliers and contract manufacturers upstream, and brand owners and retailers downstream. It captures design and formulation margin without fixed-asset intensity. |
| Customer types | US/European indie and celebrity beauty brands; global health-and-beauty retailers (Watsons, Mannings, Guardian, Cosway, Sephora); subscription-box operators (historically); Korean online platforms and TV home shopping; a Chinese distributor (Atosafe) |
| End-markets | Colour cosmetics, skincare, personal care, household detergents and oral care. Main geographies are the US, Europe and Korea, with China emerging for Atosafe. |
Company's own characterisation vs. independent view
Company view (latest management statements): Bonne describes itself as a "global cosmetics company" offering a total solution from product planning through packaging design to marketing strategy. It says it reads the market through ODM and shapes it through its own brands (CEO Kang Eun-sil, Herald Economy, Mar 2026).
Independent characterisation: In practice, Bonne's economics in FY2021–FY2024 depended on a small number of US indie-brand ODM clients. Pixi alone was 35–51% of ODM sales in 2020 (Hyundai Motor Securities, Jun and Dec 2020). This concentration explains both the FY2023–1Q24 earnings spike and the FY2025 collapse. The owned-brand business has historically consumed marketing spend; management attributed recent losses partly to marketing costs from a renewed domestic brand push over the past two years (IB Tomato, Aug 2026). Atosafe gives revenue ballast but has little visible profitability. After the change of control, the press has openly debated whether Bonne will remain an operating ODM company or become an acquisition platform for the Koo family (Cosinkorea, Aug 2026).
Strategy
Stated strategy under the previous management (Kang Eun-sil, March 2026)
CEO Kang described 2026 as the founding year of a profitability-led restructuring and a re-rating of the brand portfolio. Its three pillars were:
-
Cost-structure overhaul: exit low-margin products, cut executive pay by 10%, freeze managers' salaries, reduce benefits, and sell the HQ building to repay debt.
-
Stronger ODM: emphasise turnkey long-term reorders.
-
Faster own-brand growth: Touch in SOL on Olive Young, online first and then offline.
She said a share buyback was under review and that 2027 results would prove the restructuring (Herald Economy, 25 Mar 2026). A KRW 1.0B treasury trust followed in April 2026.
New controlling shareholder's direction (from August 2026)
Use of CB proceeds: strengthening the brand portfolio, marketing to raise brand value, expanding domestic and overseas distribution, and supply-chain efficiency (IB Tomato, Aug 2026).
Focus on existing brands: the company said it would invest in Touch in SOL at Olive Young rather than launch new brands (Edaily, Sep 2026).
Expanded financing capacity: the 10 Sep 2026 EGM removed the 20% cap on third-party share allotments and raised the combined CB/BW issuance limit to about KRW 400B. The company said this was at the investor's request (Etoday, 28 Aug 2026). Against a market cap of about KRW 42B, this capacity is a governance signal worth monitoring.
Platform hypothesis: Ventaselect added holding-company, subsidiary-control and management/financial consulting purposes to its articles. Market commentators read this as preparation for using Bonne as an M&A platform (Cosinkorea, Aug 2026). In late September 2026 the Koo family also agreed to buy 74.94% of the listed apparel company C-Site (씨싸이트) for about KRW 50.4B, which the press framed as building a K-beauty and fashion platform (Seoul Economic Daily via StockHub, 28 Sep 2026). No Bonne–C-Site transaction has been announced.
Other initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Governance remediation | Mar–Apr 2025 | New board, Transparent Management Committee, automated ERP, ISO anti-bribery and compliance certification |
| Atosafe China entry | Feb 2026 | Denti Buongiorno; further oral-care contracts under discussion |
| Olive Young channel | Mar 2026 | Touch in SOL online; offline entry targeted |
| Treasury trust | Apr 2026 | KRW 1.0B |
| Reverse split | May 2026 | Responds to KOSDAQ low-price ("coin stock") delisting rules effective 1 Jul 2026 (inferred from market context) |
| Recapitalisation and control change | Jul–Oct 2026 | See Section 11 |
Medium-term targets and guidance
No quantitative medium-term targets or formal guidance have been identified from either the old or new management. A company official said a return to profit is possible if overseas B2B business performs well (IB Tomato, Aug 2026).
Products & Services
Cosmetics ODM services
| Offering | Description | Target customer | Notes / flagship |
|---|---|---|---|
| Turnkey ODM development | Concept, colour forecasting, formulation, component and packaging development, then outsourced manufacture and assembly | Indie, celebrity and retailer private-label brands | Fabless model (IB Tomato, Aug 2026; CB Insights profile) |
| Colour cosmetics ODM | Primers, lip tints, glossy balms, mascaras and similar | US/EU indie brands, subscription boxes | Boxycharm sampling in 2019 included glossy balm; lip tint, gloss balm and essence were under discussion for 2020 (KTB, Nov 2019) |
| Skincare ODM | Toners, essences, mists, mask packs | Pixi, Kiehl's (mask packs), Russian skincare clients | US customs records for shipments to Pixi Beauty list "glycolic", "glow" and "mist" among top product keywords (Panjiva). Russian skincare orders were noted in 2023 (SK Securities, Jan 2023). |
| Indie-brand rapid development | Fast sampling and small-lot production for trend-driven brands | US indie brands | Over 170 new products in development and 62 new clients in Q1 2024 (Venturesquare, May 2024) |
| Pricing model | — | — | — |
Named ODM clients (historical, from broker and press reports): Pixi; Kendo (Kendo Brands, an LVMH incubator whose brands include Fenty and Rare Beauty); Rare Beauty; Fenty Skin; Patchology; Watsons; Cosway; Mannings; Guardian; Sephora; Stila; Lorac; Kiehl's (L'Oréal); Boxycharm. Sources: SK Securities, Jan 2024; Yuanta, Jan 2020; iNews24; Newdaily; Herald Economy. Current revenue shares by client are not publicly disclosed.
Own cosmetics brands
| Brand | Category / description | Launch | Channels and achievements | Status |
|---|---|---|---|---|
| Touch in SOL (터치인솔) | Colour cosmetics: primers, lip/shadow duos, mascara, brow | 2,012 | Sephora US (2015; about 400 doors by 2018); Ulta (2019); CVS (2020); about 2,000 Japanese drugstores; HSN; Korean home shopping; Olive Young online (Mar 2026) | Core brand; the new owner plans to concentrate marketing on Olive Young (Edaily, Sep 2026) |
| Touch in SOL No Poreblem Primer | Pore-blurring primer | — | Ranked about #9–11 in Amazon's primer category (2018) | Flagship SKU |
| Touch in SOL Metallist Lipstick & Shadow Duo | Dual-use metallic colour | — | Named as a flagship product | — |
| Stage Q (스테이지Q) | Youth-targeted colour cosmetics (ages 10–29), co-developed with Sephora China | 2,018 | Sephora China, about 250 stores by May 2019 | — |
| Medisol (메디솔) | Skincare | — | — | — |
| Miracle Island (미라클아일랜드) | Skincare/body | — | — | — |
| Forest Hill (포레스트힐) | Cleansers | — | Strong Korean home-shopping sales in 2019 (about 10 broadcasts) | — |
| MDS (e.g., "MDS Fresh Vita Mixer Cell Therapy") | Skincare | — | Named as a flagship product in 2018 | — |
Sources: Etoday, Sep 2018; Newdaily, Sep 2018; KTB, Nov 2019; Herald Economy, Mar 2026. Management states that seven brands have been launched in total (IB Tomato, Aug 2026). Pricing is not publicly disclosed.
Atosafe household and oral care
| Brand / product | Category | Specs / positioning | Channels | Notes |
|---|---|---|---|---|
| Shussler (쉬슬러) | Liquid laundry detergent | Eco-positioned | Home&Shopping, Coupang and other online channels | Main product (Dealsite, Jun 2023) |
| Milk Cotton (밀크코튼) | Fabric softener / laundry | — | Online | Main product (Dealsite, Jun 2023) |
| Denti Buongiorno (덴티 본조르노) | Toothpaste, three variants (bad-breath, gum and tartar care) | Ecocert-certified eucalyptus and sage extracts; formulated without harmful substances | Korea; China via Meitong Supply Chain (Shenzhen) | China minimum purchase of 700,000 units in 2026 (about KRW 4.3B); initial order about KRW 1.0B (Finance Scope, Feb 2026) |
Financial Narrative
Income statement (consolidated, KRW 100M)
Source: Butler (consolidated). FY2022 net income was KRW 45.83M. Margins and growth are calculated from the rounded figures.
Revenue CAGR FY2021–FY2025: −3.8% a year, falling from 538 to 460.
FY2023–FY2025 contraction: −36.9% (729 to 460).
Gross profit (FY2025 only). Revenue of KRW 460.1 × 100M less cost of sales of KRW 264.4 × 100M gives gross profit of about KRW 195.7 × 100M, a gross margin of about 42.5% (ValueLine trailing-twelve-month series to Dec 2025).
EBITDA, pre-tax income, EPS (basic and diluted), dividends per share. EBITDA and pre-tax income by year are not publicly disclosed in sources reviewed. Trailing EPS is about −KRW 1,682 to −1,685 on a post-reverse-split basis (StockHub; Google Finance). No dividends have been paid (StockHub: payout 0%; SK Securities historical tables show KRW 0 DPS).
Quarterly trajectory (consolidated, KRW 100M)
Sources: Q1 2025 from IB Tomato (Aug 2026); Q2 2025 to Q1 2026 from Google Finance; Q2 2026 from Butler. IB Tomato reports Q1 2026 as KRW 93 × 100M revenue and KRW −21 × 100M operating income, consistent after rounding.
H1 2026: revenue of about KRW 178 × 100M, down 29.6% YoY against about KRW 254 × 100M in H1 2025. Operating loss of about KRW −44 × 100M. These are derived figures.
- Q1 2024 reference (as originally reported, before later re-audit): revenue 207.7, operating income 31.3, net income 24.6 (KRW 100M). On a stand-alone basis, the US accounted for 65% of exports and 45% of consolidated sales (Venturesquare, May 2024).
Balance sheet and liquidity (latest available points)
Total assets, total debt split (short and long term), net debt, goodwill and intangibles (Atosafe goodwill is likely), and working capital for FY2021–FY2025 are not publicly disclosed in sources reviewed.
Pro-forma debt note. The August 2026 CBs add KRW 20.0B of face-value debt. They carry a 3% coupon and 5% yield-to-maturity, with 106.43% of principal repayable at maturity (IB Tomato, Aug 2026). Unless converted, this roughly doubles financial liabilities relative to the reported debt ratio, a derived inference. In March 2026 management said that selling the HQ building would reduce borrowings, which confirms that bank debt exists; the amount is not disclosed.
Ratios
Trailing ratios (StockHub, Oct 2026): ROE −48.28%; ROA −31.9%; operating margin −16.86%; net margin −77.25%; revenue growth −22.1%.
- ROIC, interest coverage, net debt/EBITDA, asset turnover and cash-conversion cycle: not publicly disclosed in sources reviewed. EBITDA is negative on a trailing basis (EV/EBITDA −3.40, StockHub), so net debt/EBITDA and interest coverage are not meaningful.
Commentary on trends, inflections and drivers
-
FY2021–FY2023 growth phase. Revenue rose from KRW 538 to 729 × 100M. Drivers were the full-year consolidation of Atosafe from FY2021 and the US indie-beauty boom. Brokers in early 2024 described US exposure of about 75% and forecast record FY2024 revenue of about KRW 1,105 × 100M with operating income of about 125 (SK Securities, Jan 2024). These forecasts were badly missed: actual FY2024 revenue was 687.
-
Accounting credibility shock (late 2024 to April 2025). The SFC found FY2022–FY2023 inventory overstated. The resulting trading halt, management overhaul and auditor designation coincided with a sharp fall in reported earnings: FY2024 operating income of 17 against 67 in FY2023.
-
FY2025 collapse. Revenue fell 33% to 460 and the operating loss reached −83. Management attributed losses partly to higher domestic brand-marketing spend. It said profitability depends on overseas B2B (ODM) recovery (IB Tomato, Aug 2026). The quarterly run-rate fell from KRW 131 × 100M in Q1 2025 to 85–93 by Q4 2025 to Q2 2026, with a steady operating loss of about −20 to −23 a quarter. Mid-2025 SG&A of about 65–67 a quarter is far too high for that revenue base.
-
Liquidity squeeze to recapitalisation (2026). Cash fell from 78.5 to 53.8 in Q1 2026. The company stated that August's capital raise was needed for product costs and salaries, noting that overseas receivables take about three months to collect (Edaily, Sep 2026). The KRW 22.2B injection extends runway materially relative to the cash burn implied by about KRW −20 × 100M of quarterly operating losses (derived), but it does not fix the cost base.
-
Inflection watch. No evidence of a revenue turn yet: Q2 2026 revenue of 85 is still about 31% below Q2 2025.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Business | Key facts |
|---|---|---|---|
Bonne Co., Ltd. | Listed parent | Cosmetics ODM and own brands | Fabless model; HQ in Seoul |
Atosafe Co., Ltd. (아토세이프) | Consolidated subsidiary | Detergent, fabric softener, oral care (Shussler, Milk Cotton, Denti Buongiorno) | 68.9% acquired Feb 2021 for KRW 24.8B. Founded 2010. Now IB Capital and TS Investment each held 5.5% via convertible preferred shares (2021). |
Segment Revenue
| Segment | Q2-2026 share (%) | Q2-2026 revenue (KRW 100M, derived) |
|---|---|---|
Cosmetics (ODM and brands) | 59 | 50 |
Detergent (Atosafe) | 39 | 33 |
Other | 2 | 2 |
Total | 100 | 85 |
Revenue by Segment (%)
| Metric | FY2020 |
|---|---|
ODM share of revenue (%) | 64 |
Brand share of revenue (%) | 34 |
Other share of revenue (%) | 2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (KRW)
| Metric | FY2022 |
|---|---|
Atosafe revenue (KRW 100M) | 351 |
Atosafe operating profit (KRW 100M) | 20 |
Income Statement (KRW) and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 538 | 607 | 729 | 687 | 460 |
Operating income (KRW 100M) | -10 | 7 | 67 | 17 | -83 |
Net income (KRW 100M) | -40 | 0.46 | 5 | -94 | -159 |
Revenue growth YoY (%) | — | 12.8 | 20.1 | -5.8 | -33.0 |
Operating margin (%) | -1.9 | 1.2 | 9.2 | 2.5 | -18.0 |
Net margin (%) | -7.4 | 0.1 | 0.7 | -13.7 | -34.6 |
Income Statement (KRW)
| Metric | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|---|
Revenue (KRW 100M) | 131 | 123.4 | 120.2 | 85.7 | 92.7 | 85 |
Operating income (KRW 100M) | -15 | -22.2 | -20.3 | -22.7 | -20.6 | -23 |
SG&A (KRW 100M) | — | 67.0 | 65.3 | 41.5 | 60.7 | — |
R&D expense (KRW 100M) | — | 0.97 | 1.04 | 0.84 | 1.00 | — |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Cash and cash equivalents | KRW 78.5 × 100M | 31 Dec 2025 (IB Tomato) |
Cash and cash equivalents | KRW 53.8 × 100M | 31 Mar 2026 (IB Tomato) |
Operating cash flow | about KRW −6 × 100M | Q1 2026 (IB Tomato) |
Equity (as cited in embezzlement disclosure) | KRW 382.8 × 100M | Disclosure dated 18 Aug 2026 (StockHub/Edaily); balance-sheet date not stated |
Debt-to-equity (liabilities / equity) | 51.4% | StockHub, latest reported |
Current ratio | 97.5% | StockHub, latest reported |
New capital, Aug 2026 | KRW 22.2B (private placement 2.2B plus CBs 20.0B) | Dealsite; Cosinkorea |
Treasury trust | KRW 1.0B (Eugene Investment & Securities), 16 Apr–16 Oct 2026 | StockHub (KIND) |
Financial Analysis
| Item | As originally reported | As currently shown | Explanation |
|---|---|---|---|
FY2022 net assets and net income | Higher | Reduced by KRW 1.012B | SFC inventory-overstatement correction (Cosinkorea, Apr 2025) |
FY2023 net income | Loss (as reported) | Increased by KRW 0.8B, turning to profit; net assets reduced by KRW 0.15B | Same restatement |
FY2024 operating income (KRW 100M) | 25 | 17 | Cosinkorea (Apr 2025) cites 25; Butler shows 17. Likely a later amendment or prior-period re-audit (Etoday, Aug 2026). |
FY2024 net income (KRW 100M) | -57 | -94 | Same discrepancy |
ROE | -94.0% (Butler) | -48.28% (StockHub) | Different equity bases and periods |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating margin (%) | -1.9 | 1.2 | 9.2 | 2.5 | -18.0 |
Net margin (%) | -7.4 | 0.1 | 0.7 | -13.7 | -34.6 |
Revenue by Region (%)
| Metric | FY2020 | FY2024F | Q1-2024 |
|---|---|---|---|
North America share of exports (%) | 62 | — | — |
US share of revenue, broker basis (%) | — | 75 | — |
US share of exports, stand-alone (%) | — | — | 65 |
US share of consolidated revenue (%) | — | — | 45 |
Segment Overview
| Segment | Korea | US | Europe/UK | China | Other Asia |
|---|---|---|---|---|---|
Cosmetics ODM | Minor | Dominant (Pixi, Kendo-linked brands, Rare Beauty, Fenty Skin) | Significant (UK, France; Pixi is UK-founded) | Minor | Watsons, Mannings, Guardian, Cosway retail private label |
Own brands | Home shopping, Olive Young (2026) | Sephora/Ulta/CVS (historical) | — | Stage Q via Sephora China (historical) | Japanese drugstores (historical) |
Atosafe | Dominant (online, TV shopping) | — | — | New from 2026 (Denti Buongiorno) | — |
Valuation Multiples (KRW)
| Metric | Jan-2020 | Jan-2024 | Mar-2026 | Jul-2026 | Oct-2026 |
|---|---|---|---|---|---|
Market capitalization (KRW 100M) | 1,174 | 930 | 167 | 141 | 423 |
Share Price History
| Date | Price | Basis | Source |
|---|---|---|---|
3 Jan 2020 | 3,825 | Pre-split | Yuanta |
15 Apr 2025 | 1,228 | Pre-split (about 6,140 split-adjusted at an inferred 5:1) | Cosinkorea |
May 2026 | 3,235 | Post-split, at the time of the reverse split | IB Tomato |
30 Jul 2026 | 1,290 | Post-split | Money Today |
31 Jul 2026 | 1,677 | Post-split, +30% | ValueLine |
5 Aug 2026 | 3,675 | Post-split, limit-up | Money Today |
52-week high | 9,680 | — | StockHub |
14 Oct 2026 | 5,760 | — | StockHub |
15 Oct 2026 | 5,040 | −12.5% | StockHub |
Valuation Multiples
| Multiple | Bonne | Notes / peers |
|---|---|---|
P/E (trailing) | n/m (loss) | — |
P/B | 1.51 (StockHub) / 1.82 (Butler) | Amorepacific 1.76x; Kolmar Korea 3.55x; APR 23.46x (StockHub peer note) |
EV/EBITDA | -3.40 (StockHub) | Not meaningful with negative EBITDA |
P/S (trailing) | about 1.0 (423 / 422, derived) | Korean personal-products median P/S about 0.9x (Simply Wall St, 2025) |
Valuation of the founder block | KRW 3,984 per share (revised SPA) | Current price KRW 5,040 |
Capital Instruments
| Instrument | Issued | Amount (KRW Bn) | Coupon / YTM | Conversion price (KRW) | Maturity / put | Holder |
|---|---|---|---|---|---|---|
13th CB (private) | Feb 2021 | 12.0 | 0% / 0% | 2,785, refixed to 1,950 (pre-split) | 5 years (2026) | Now IB Capital, TS Investment. |
5th CB (private) | 28 Aug 2026 | 10.0 | 3% / 5% | 1,396 (no refixing) | Conversion from Aug 2027; 106.43% at maturity; put option available | Koo Mi-hyun |
6th CB (private) | 28 Aug 2026 | 10.0 | 3% / 5% | 1,396 (no refixing) | Same as 5th CB | Ventaselect |
Bank borrowings | — | — | — | — | — | Management plans to repay with the building sale |
Analyst Conclusions
Guidance and consensus
There is no formal management guidance and no sell-side consensus. The only forward-looking statements are qualitative: a turnaround dependent on overseas B2B recovery, and CB proceeds directed to brand marketing, distribution and the supply chain.
Bull case
-
Recapitalised and sponsor-backed. KRW 22.2B of fresh capital, about 1.2 times FY2025 cash burn on an operating basis (derived), together with a controlling family that has substantial liquidity from the Ourhome sale (reportedly about KRW 870B in total proceeds to the sellers, per IB Tomato), removes near-term solvency and listing risk.
-
Operating leverage from a reset cost base. Q4 2025 SG&A of KRW 41.5 × 100M shows that costs can be compressed. With gross margins of about 42% (FY2025), stabilising revenue at about KRW 90–100 × 100M a quarter with SG&A held near 40 would move operating income toward breakeven (illustrative, derived).
-
Platform optionality. The Koo family's simultaneous acquisition of C-Site, and Ventaselect's holding-company purposes, suggest Bonne could become the beauty arm of a consumer group, with acquisition or asset-injection upside.
Bear case
-
Structural share loss in ODM. Peers with plants and OTC capability grew 10–19% in FY2025 while Bonne fell 33%. A fabless, sub-scale model may not regain US indie clients.
-
Dilution and minority-unfriendly structure. CB conversion at KRW 1,396 (14.33M shares against 8.39M outstanding), no refixing protection for minorities, removal of the 20% placement cap and about KRW 400B of mezzanine headroom create the potential for repeated value transfer to the controller.
-
Governance track record. Accounting fraud findings, an embezzlement case involving two CEOs, a late periodic filing and active minority litigation within 21 months. The board was reconstituted before closing, and the share price trades well above the control-deal price.
Catalysts and monitorables (next 12 months)
-
Q3 2026 report (due mid-November 2026): revenue trajectory, SG&A and cash.
-
Confirmation that the founder's 21.33% block transferred on 12 Oct 2026, and any further changes to the controller's holdings.
-
Court rulings on the injunction appeal and the suit to invalidate the new shares; listing of the 699,473 new shares.
-
Announced strategy from the new management: brand investment, any M&A or asset injections, and any links with C-Site.
-
Any further CB, BW or third-party placements under the expanded articles.
-
Olive Young offline roll-out for Touch in SOL; Atosafe's delivery against the China minimum purchase commitment.
-
HQ building sale and debt reduction.
-
FY2026 annual audit opinion (with the designated auditor) and the outcome of the embezzlement recovery.
-
Compliance with KOSDAQ market-cap and price thresholds.
-
CB conversion window opening in August 2027 (outside the 12-month window but likely to affect share-price behaviour).
Concluding analyst verdict
Bonne is no longer an operating growth story. It is a special-situation control-change equity. The fundamentals are weak. Revenue has fallen for two straight years to KRW 46.0B (FY2025, −33%), the business has posted an operating loss of about KRW 2B in each of the last five reported quarters, and nothing in the H1 2026 results points to a demand inflection. The fabless ODM model that let Bonne ride the US indie boom cheaply is now a liability. Larger Korean peers with manufacturing, CGMP and OTC capability are capturing the same demand, and Bonne's dependence on a few US clients has proved costly. Atosafe provides revenue ballast but no visible profit cushion.
Balance-sheet risk has been largely neutralised by the August 2026 recapitalisation. Koo Mi-hyun's family now controls the board and, after CB conversion, would hold about 72% of the fully diluted equity. That is both the bull and the bear case. A deep-pocketed sponsor with consumer-industry experience can fund a brand rebuild and could use Bonne as a listed platform for acquisitions. However, the deal terms, including a conversion price of KRW 1,396 with no refixing and articles amended to allow very large mezzanine issuance and uncapped third-party allotments, give the controller considerable room to reshape the shareholder base. Minority investors should not assume their interests are aligned.
At KRW 5,040 the market values the company at about 1.0 times trailing sales and 1.5–1.8 times book. That is not cheap for a business losing money at the operating line, and it already prices in a sponsor premium above the KRW 3,984 control price. Governance history, including the SFC sanction, the embezzlement disclosure, a late filing and ongoing litigation, argues for a high risk premium. Verdict: speculative and event-driven only. Fundamental investors should wait for (1) the new management's articulated strategy, (2) at least two quarters of narrowing losses, and (3) clarity on capital allocation under the expanded financing authorities before considering exposure.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background | Source |
|---|---|---|---|---|
Yeo Min-ju (여민주) | CEO (representative director) | Since 10 Sep 2026 | Reported to come from Canel (카넬), a company formerly headed by Koo Mi-hyun. Education and age not disclosed. | Dealsite, 23 Sep 2026 |
Koo Mi-hyun (구미현) | Inside director; largest shareholder | Since 10 Sep 2026 | Eldest daughter of the late Koo Ja-hak (Ourhome founder) and granddaughter of LG founder Koo In-hwoi. Became Ourhome CEO-chairwoman in 2024 during a family dispute, then sold her Ourhome stake to Hanwha Hotels & Resorts and stepped back. | IB Tomato; Cosinkorea, Aug 2026 |
Lee Young-yeol (이영열) | Inside director | Since 10 Sep 2026 | Former Vice Chairman of Ourhome | Dealsite, 23 Sep 2026 |
New outside directors and statutory auditor | — | Since 10 Sep 2026 | — | Dealsite |
Executive Leadership Team
| Name | Role | Notes |
|---|---|---|
Kang Eun-sil (강은실) | CEO, Mar 2025 to Sep 2026 | Co-founder, previously vice-president. Named in the Aug 2026 embezzlement/breach-of-trust disclosure. She was also one of the related-party sellers of shares. |
Nam Byung-soo (남병수) | Vice-president, CFO | Former CFO of HelloVision and CJ Olive Networks (also head of its DS division) |
Noh Seung-kwon (노승권) | Outside director | Lawyer, Bae, Kim & Lee (법무법인 태평양) |
Koo Sung-hoe (구성회) | Outside director | CPA, Samduk Accounting |
Song Young-kwan (송영관) | Statutory auditor | Tax accountant (Olim Tax), former National Tax Service official |
Lim Sung-ki (임성기) | Founder; CEO 2009 to Mar 2025 | Stepped down after the SFC sanction; held 21.33–21.34%. Named in the Aug 2026 disclosure. |
Major Shareholders
| Holder | Shares | % | Date / note | Source |
|---|---|---|---|---|
Lim Sung-ki and 4 related parties (pre-deal) | 3,162,940 | 37.70 | 31 Jul 2026 SPA | Dealsite; Money Today |
of which Lim Sung-ki | 1,790,123 | 21.33 | Transfer to Koo scheduled 12 Oct 2026 | Dealsite |
of which Lim Ye-won, Kim Mi, Lim Jun-hyuk, Kang Eun-sil | 1,372,817 | 16.36 | Transferred to Koo on 10 Sep 2026 | Dealsite |
Koo Mi-hyun (after closing) | 3,162,940 | about 37.7 (pre-dilution) | Large-holding report of 17.49M shares including CB conversion rights (17 Sep 2026) | StockHub; IB Tomato |
Ventaselect Co., Ltd. | 0 common (holds 6th CB convertible into 7,163,323 shares) | — | Owned 44% each by Koo's son Lee Seok-ju and daughter Lee Kyung-a; CEO Lee Young-pyo, former Ourhome management president | IB Tomato, Aug 2026 |
H Investment Partnership (에이치투자조합) | 699,473 | about 7.7 (post-issue, derived) | Private placement at KRW 3,150 | Edaily; StockHub |
Minority (small) shareholders | 22,377,125 (pre-split) | 53.33 | 10,288 holders (99.92% of holders), 31 Mar 2026 | Edaily, Sep 2026 |
Treasury shares | — | 5.02 | Oct 2026 | Butler |
Foreign ownership | — | about 0.0 | Oct 2026 | StockHub |
Competitive Landscape
Peer Comparison FY2024
| Company | FY revenue (KRW 100M) | Revenue growth (%) | Operating income (KRW 100M) | OPM (%) | Source |
|---|---|---|---|---|---|
Bonne (FY2025) | 460 | -33.0 | -83 | -18.0 | Butler |
Kolmar Korea (FY2025) | 27,224 | 11.0 | 2,396 | 8.8 | Kukinews, Feb 2026; growth derived against FY2024 revenue of 24,521 |
Cosmax (FY2025) | 23,988 | 10.7 | 1,958 | 8.2 | Kukinews, Feb 2026 |
Englewood Lab (FY2025) | 2,168 | 19.0 | 374 | 17.3 | Butler |
Cosmecca Korea (FY2024) | — | — | 604 | — | Q3 2025: revenue 1,824 and operating income 272 (Kukinews). |
C&C International (FY2024) | — | — | 290 | — | Cosinkorea |
Korea Cosmetics Manufacturing (FY2024) | — | — | 265 | — | Cosinkorea |
Intercos Korea (FY2024) | — | — | 230 | — | Cosinkorea |
Hansol Life Science (FY2024) | — | — | 196 | — | Cosinkorea |
B&B Korea (FY2024) | — | — | 166 | — | Cosinkorea |
Encos (FY2024) | — | — | 165 | — | Cosinkorea |



